Alyeska Investment Group
MRNS

Alyeska Investment Group’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Alyeska Investment Group’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-218,837
Closed -$3.93M – 827
2021
Q2 		$3.93M Sell
218,837
-412,373
-65% -$6.63M 0.05% 389
2021
Q1 		$9.77M Sell
631,210
-615,363
-49% -$8.9M 0.13% 207
2020
Q4 		$15.2M Buy
1,246,573
+314,392
+34% +$4.38M 0.21% 148
2020
Q3 		$12M Buy
932,181
+228,977
+33% +$1.98M 0.18% 164
2020
Q2 		$7.14M Buy
703,204
+139,424
+25% +$1.28M 0.11% 228
2020
Q1 		$4.58M Buy
563,780
+13,277
+2% +$115K 0.09% 198
2019
Q4 		$4.76M Buy
550,503
+274,365
+99% +$1.54M 0.06% 232
2019
Q3 		$1.7M Buy
276,138
+25,659
+10% +$207K 0.02% 297
2019
Q2 		$4.16M Buy
+250,479
New +$4.35M 0.05% 258

Other funds holding MRNS

LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Alyeska Investment Group's MRNS Position: Q3 2021 in Review

Alyeska Investment Group sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2021, closing a stake of 218,837 shares — an estimated $3.93M sold.

Alyeska Investment Group first reported a position in MRNS in Q2 2019 and held it in 9 quarters. The position peaked at $15.2M in Q4 2020. 82 funds tracked by Wall St. Rank hold MRNS as of Q3 2021.

  • Alyeska Investment Group reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 218,837 Marinus Pharmaceuticals, Inc shares in Q3 2021, an estimated $3.93M.
  • Alyeska Investment Group first reported a position in Marinus Pharmaceuticals, Inc in Q2 2019 and held it in 9 quarters.
  • Alyeska Investment Group's Marinus Pharmaceuticals, Inc position peaked at $15.2M in Q4 2020.
  • 82 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2021.

Based on Alyeska Investment Group's 13F filing for Q3 2021, filed 15 Nov 2021.